Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma - Episode 5

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

, , , , ,

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

EP. 1: Current Treatment Options in First-line FL
EP. 2: ASH 2023 Updates on Frontline Therapies in FL
EP. 3: Current Treatment Options in Second-line FL
EP. 4: CAR T-cells as Third-line and Beyond Therapy for FL
Now Viewing
EP. 5: Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
EP. 6: Tazemetostat as Third-line and Beyond Therapy for FL
EP. 7: Zanubrutinib as Third-Line and Beyond Therapy for FL
EP. 8: Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
EP. 9: Choosing CAR T-cells as Third-line and Beyond Therapy for FL
EP. 10: Sequencing Immunotherapy in the Third-line and Beyond Setting for FL
EP. 11: Unmet Needs in Treating Relapsed/Refractory FL
EP. 12: Current Treatment Options in First-Line MCL
EP. 13: ASH 2023 Updates on Frontline Therapies in MCL
EP. 14: Current Treatment Options in Second-line MCL
EP. 15: Current Treatment Options in Third-line MCL
EP. 16: Sequencing Therapies in the Third-Line and Beyond Setting for MCL
EP. 17: Future Directions and Unmet Needs in Relapsed/Refractory MCL

Related Content:

Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell LymphomaMayo ClinicDana-Farber Cancer InstituteWeill Cornell Medical College Sandra & Edward Meyer Cancer CenterMoffitt Cancer CenterHematologic OncologyOncLive Peer Exchange®
Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi
Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease